Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

Pricing
StakeholdersFunding & InvestmentInvestorsAngel Investors
8 Organisations

Angel Investors

Individual high-net-worth investors providing early-stage capital to psychedelic startups and research initiatives.

All Organisations

Bicycle Day Ventures

Bicycle Day Ventures is tracked as a syndicate/network investor that may channel capital into psychedelic and adjacent mental-health ventures.

View Profile

Gaingels

Gaingels is tracked as a syndicate/network investor that may channel capital into psychedelic and adjacent mental-health ventures.

View Profile

Kevin O'Leary

Kevin O'Leary is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

View Profile

Matt Mullenweg

Matt Mullenweg is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

View Profile

Mike Novogratz

Mike Novogratz is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

View Profile

Mission Club

Mission Club is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

View Profile

Peter Thiel

Angel investor and entrepreneur with publicly documented participation in atai Life Sciences financing rounds tied to psychedelic drug-development.

View Profile

Tim Ferriss

Tim Ferriss is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

View Profile

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.